Ms. Weisner is currently an independent board member of Oyster Point Pharma, Inc.
(2019-present) (NASDAQ: OYST), and a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of pharmaceutical therapies to treat
ocular surface diseases. Ms. Weisner is also an independent board member and audit
committee member at Glaukos Corp. (2014-present) (NYSE: GKOS), an ophthalmic medical
technology and pharmaceutical company.

From 2011 to 2019, Ms. Weisner was the corporate vice president, general counsel of
Edwards Lifesciences Corporation. Prior to that time, from 2002 to 2009, Ms. Weisner
served a variety of roles for Advanced Medical Optics, Inc. (acquired by Abbott
Laboratories), including corporate vice president, general counsel and secretary;
executive vice president, administration, general counsel and secretary; and executive
vice president, administration and secretary. Prior to that, Ms. Weisner served as
corporate counsel and assistant secretary; and then vice president, assistant general
counsel and assistant secretary at Allergan, Inc. Ms. Weisner holds a B.A. from
California State University, Fullerton, a J.D. from Loyola Law School, Los Angeles, and
began her legal career as an associate at the law firm of O’Melveny & Myers LLP.